OncoMatch/Clinical Trials/NCT05088356
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Is NCT05088356 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for allogeneic hematopoietic cell transplantation (hct).
Treatment: Purified regulatory T-cells (Treg) plus CD34+ HSPC · Fludarabine · Melphalan · CliniMACS CD34 Reagent System · Tacrolimus · Cyclophosphamide · Plerixafor · Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent · Thiotepa · Mycophenolate Mofetil (MMF) · Ruxolitinib — Reduced intensity conditioning (RIC) has emerged and been increasingly adopted as a modality to allow preparative conditioning pre transplant to be tolerated by older adults or those patients that are otherwise unfit for myeloablative conditioning. In this study, we aim to use RIC followed by matched related/unrelated donor, 7/8 matched related/unrelated donor, or haploidentical donor peripheral blood stem cell transplantation. Standard strategies to control the alloreactivity following HCT utilize immunosuppressive or cytotoxic medications. In this study, we explore donor graft engineering to enrich for immmunoregulatory populations to facilitate post transplantation immune reconstitution while minimizing graft versus host disease (GVHD) with post-transplant immunosuppressive agents.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lab requirements
Kidney function
Calculated creatinine clearance ≥ 50 mL/min or creatinine < 2.0 mg/dL
Liver function
SGPT and SGOT ≤ 3 x ULN, unless elevated secondary to disease; Total bilirubin ≤ 2 x ULN (patients with Gilbert's syndrome may be included at the discretion of the PI or where hemolysis has been excluded)
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 45%
LVEF ≥ 45%; DLCO ≥ 50%; Calculated creatinine clearance ≥ 50 mL/min or creatinine < 2.0 mg/dL; SGPT and SGOT ≤ 3 x ULN, unless elevated secondary to disease; Total bilirubin ≤ 2 x ULN (patients with Gilbert's syndrome may be included at the discretion of the PI or where hemolysis has been excluded)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University · Stanford, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify